医学
瘀斑
痤疮
不利影响
皮肤病科
外科
随机对照试验
增生性瘢痕
内科学
作者
John Joseph,Ava Shamban,Laura Eaton,Alayne Lehman,Steven R. Cohen,James Spencer,Suzanne Bruce,Pearl E. Grimes,Ruth Tedaldi,Valerie Callender,Phillip Werschler
出处
期刊:Dermatologic Surgery
[Lippincott Williams & Wilkins]
日期:2019-03-02
卷期号:45 (12): 1558-1566
被引量:18
标识
DOI:10.1097/dss.0000000000001863
摘要
This trial evaluated the effectiveness and safety of Bellafill for full-face acne scar treatment.In this open-label, nonrandomized, multicenter pilot study investigating the use of polymethylmethacrylate for full-face atrophic acne scar correction, 42 adult subjects with a mean age of 43 years were treated and assessed for safety and effectiveness at Months 4 and 7. There were no hypersensitivity reactions to pretreatment skin testing or during scar treatments.At 4 and 7 months after initial treatment, 92% and 95% of subjects, respectively, were responders with ≥1-point improvement on the 5-point Acne Scar Assessment Scale. Subjects reported very high levels of improvement on the Global Aesthetic Improvement Scale (GAIS), with 95% of subjects reporting "improved or better" at 4 months and 90% at 7 months. The outcome of the physician GAIS was also high with 92% of patients classified as "improved or better" at 4 months and 97% at 7 months. There were only 2 device-related adverse events, both mild events related to Bellafill skin test (bruising, ecchymosis). There were no serious adverse events in response to the treatment product in this short-term follow-up study.Polymethylmethacrylate is effective for treating full-face acne scarring. Clinicaltrials.gov #NCT02642627.
科研通智能强力驱动
Strongly Powered by AbleSci AI